Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Sep 16, 2010

Premium

Title: Composition Comprising Double-Stranded RNA That Inhibits Expression of NEU3 and Method of Treating Cancer

Patent Number: 7,795,233

Filed: Nov. 15, 2005 PCT Filed: Nov. 15, 2005

Lead Inventor: Taeko Miyagi, Miyagi Cancer Center Research Institute

The invention, the patent's abstract states, comprises "a pharmaceutical composition for treating cancer or diabetes [containing a] double-stranded RNA" of a pre-defined sequence "of 20 to 30 nucleotides that is identical to a partial sequence of a gene encoding human plasma membrane-associated sialidase" and inhibits the gene.


Title: Viral and Viral-Associated miRNAs and Uses Thereof

Patent Number: 7,795,419

Filed: Aug. 28, 2006

Lead Inventor: Isaac Bentwich, Rosetta Genomics

The patent, its abstract states, claims "novel polynucleotides associated with viral infections. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed," as are "methods that can be used to identify modulators of viral infections."


Title: Functional and Hyper-Functional siRNA Directed Against Bcl-2

Patent Number: 7,795,420

Filed: Oct. 17, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing Bcl-2."


Title: siRNA Targeting Apolipoprotein B

Patent Number: 7,795,421

Filed: Oct. 29, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing ApoB."


Title: RNA Interference-Mediated Inhibition of Hypoxia-Inducible Factor 1 Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,795,422

Filed: July 17, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating hypoxia-inducible factor [1] gene expression using short interfering nucleic acid molecules," the patent's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of HIF1 gene expression and/or activity by RNA interference using small nucleic acid molecules."


Title: Compositions Comprising miR-34 Therapeutic Agents for Treating Cancer

Application Number: 20100227909

Filed: May 5, 2008

Lead Inventor: Michele Cleary, Merck

"The invention generally relates to compositions comprising miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer," the patent application's abstract states.


Title: Gene Fusion Targeted Therapy

Application Number: 20100227910

Filed: March 3, 2010

Lead Inventor: Arul Chinnaiyan, University of Michigan

The invention "relates to compositions and methods for cancer therapy, including but not limited to targeted inhibition of cancer markers," the patent application's abstract states. "In particular, the … invention relates to recurrent gene fusions as clinical targets for prostate cancer."

The application specifically claims an siRNA "that inhibits the expression of an ERG gene in a cell."


Title: RNA Interference-Mediated Inhibition of Chromosome Translocation Gene Expression Using Short Interfering Nucleic Acid

Application Number: 20100227911

Filed: March 4, 2010

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating chromosomal translocation gene expression using short interfering nucleic acid molecules," according to the patent application's abstract. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of chromosomal translocation gene expression and/or activity by RNA interference using small nucleic acid molecules," including BCR-ABL, ERG, EWS-ERG, TEL-AML1, EWS-FLI1, TLS-FUS, PAX3-FKHR, and/or AML1-ETO fusion genes.


Title: RNA Interference-Mediated Inhibition of Myostatin Gene Expression Using Short Interfering Nucleic Acid

Application Number: 20100227912

Filed: April 22, 2010

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating myostatin gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of myostatin gene expression and/or activity by RNA interference using small nucleic acid molecules."


Title: Compositions and Methods for Inhibiting Expression of a Gene from the JC Virus

Application Number: 20100227915

Filed: March 9, 2010

Lead Inventor: Pamela Tan, Alnylam Pharmaceuticals

"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the JC virus comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC virus," the patent application's abstract states. "The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC virus in a cell."


Title: RNA Interference-Mediated Inhibition of Proliferating Cell Nuclear Antigen Gene Expression Using Short Interfering Nucleic Acid

Application Number: 20100228018

Filed: April 22, 2010

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating PCNA gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PCNA gene expression and/or activity by RNA interference using small nucleic acid molecules … [which] are useful in the treatment of cancer or restenosis or other proliferative diseases, disorders, or conditions."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.